Answers are grounded in this paper and cite their sources.
Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.
No takes yet. Share an insight, caveat, or question.
Gramont et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: